AZD-1236
Based on 1 Customer Validation
AZD-1236 is a dual inhibitor of MMP-9 and MMP-12. AZD-1236 selectively inhibits the activities of MMP-9 and MMP-12. AZD-1236 regulates biomarkers, reduces elastin degradation, and decreases lymphocyte levels in sputum and blood. AZD-1236 can be used for research related to chronic obstructive pulmonary disease.
For research use only. We do not sell to patients.
- Purity: 98.01%
- CAS No.: 459814-89-2
- Formula: C15H19ClN4O5S
- Molecular Weight:402.85
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
|
MMP-9 |
MMP-12 |
In Vitro
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 459814-89-2
-
Appearance Solid
-
Molecular Weight 402.85
-
Formula C15H19ClN4O5S
-
Color White to off-white (Solid)
-
SMILES
C[C@@]1(NC(NC1=O)=O)CS(=O)(N2CCC(CC2)OC3=CC=C(C=N3)Cl)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Shoari A, et al. Therapeutic potential of inhibitors of gelatinases MMP-2 and MMP-9 for the treatment of breast cancer. The FEBS journal. 2026 Jul;293(13):4014-4042. [Content Brief]
[3]. Magnussen H, et al. Safety and tolerability of an oral MMP-9 and -12 inhibitor, AZD1236, in patients with moderate-to-severe COPD: a randomised controlled 6-week trial. Pulmonary pharmacology & therapeutics. 2011 Oct;24(5):563-70. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)